硝基苯甲酸盐 | 6786-32-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 硝基苯甲酸盐
• 英文名称: Benzoylnitrat
• 英文别名: Nitro benzoate
• CAS: 6786-32-9
• 化学式: C₇H₅NO₄
• 分子量: 167.121
• InChiKey: JBCXQJHXIYZCNI-UHFFFAOYSA-N

物化性质

• 熔点：
  40-50 °C
• 沸点：
  295.67°C (rough estimate)
• 密度：
  1.5216 (rough estimate)
• 溶解度：
  miscible with common organic solvents.

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  硝基苯甲酸盐 、 硝基苯 生成 间硝基苯甲酸
  参考文献：
  名称：

  Francis, Chemische Berichte, 1906, vol. 39, p. 3801

  摘要：

  DOI：
• 作为产物：
  描述：

  silver benzoate 在 ClNO₂ (g) 作用下， 生成 硝基苯甲酸盐
  参考文献：
  名称：

  Geometric and electronic structures of benzoyl nitrite and benzoyl nitrate

  摘要：

  The electronic structures of benzoyl nitrite (C6H5C(O)ONO) and benzoyl nitrate (C6H5C(O)ONO) have been studied by Hel photoelectron spectroscopy (PES) and quantum chemical calculations. The photoelectron spectra are assigned with the help of the outer valence Green's function (OVGF) calculations. The first vertical ionization energies Of C6H5C(O)ONO and C6H5C(O)ONO2 are determined to be 9.20 and 9.54 eV, respectively. According to the results of theoretical calculations, it can be concluded that a planar C-C(O)-O-N-O skeleton in C6H5C(O)ONO and a planar C-C(O)-O-N skeleton in C6H5C(O)ONO2 are the stable structures in the gas phase. (C) 2007 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.molstruc.2007.07.037
• 作为试剂：
  描述：

  正丙基苯 在 large port mordenite 硝基苯甲酸盐 作用下， 以 四氯化碳 为溶剂， 反应 2.17h， 生成 1-硝基-2-丙基苯 、 1-硝基-3-丙基-苯 、 1-硝基-4-正-丙基苯
  参考文献：
  名称：

  Para-selective mononitration of alkylbenzenes under mild conditions by use of benzoyl nitrate in the presence of a zeolite catalyst

  摘要：

  DOI：

  10.1016/s0040-4039(01)93779-7

文献信息

• [EN] WNT PATHWAY ANTAGONISTS<br/>[FR] ANTAGONISTES DE LA VOIE WNT
  申请人：SIENA BIOTECH SPA

  公开号：WO2011042145A1

  公开（公告）日：2011-04-14

  The present invention relates to known and novel compounds of formula (I) as herein described and pharmaceutical compositions thereof. The compounds of formula (I) have inhibitory effect on the Wnt pathway and are therefore useful in the preparation of a medicament, in particular for the treatment of cancer.

  本发明涉及如下所述的已知和新颖的化合物（I）的公式及其药物组成。公式（I）的化合物对Wnt途径具有抑制作用，因此在制备药物方面特别适用于治疗癌症。
• Microsomal triglyceride transfer protein inhibitor
  申请人：Pfizer Inc

  公开号：US20040132745A1

  公开（公告）日：2004-07-08

  The present invention provides inhibitors of microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (Apo B) secretion having Formula (I) which are useful for the treatment of obesity and related diseases, as well as prevention and treatment of atherosclerosis and its clinical sequelae, for lowering serum lipids, and in the prevention and treatment of related diseases. The invention further relates to pharmaceutical compositions comprising the compounds of the present invention and to methods of treating obesity, atherosclerosis, and related diseases and/or conditions with the compounds of the present invention, either alone or in combination with other medicaments, including lipid-lowering agents. 1

  本发明提供了具有公式(I)的微粒体甘油三酯转运蛋白（MTP）和/或载脂蛋白B（Apo B）分泌抑制剂，用于治疗肥胖及相关疾病，以及预防和治疗动脉粥样硬化和其临床后遗症，降低血清脂质，以及预防和治疗相关疾病。本发明还涉及包含本发明化合物的药物组合物，以及使用本发明化合物单独或与其他药物（包括降脂药）联合治疗肥胖、动脉粥样硬化和相关疾病/状况的方法。
• Pyrrolobenzodiazepines
  申请人：Spirogen Limited

  公开号：US20030120069A1

  公开（公告）日：2003-06-26

  Compounds of the formulae Ia and Ib: 1 wherein: A is CH 2 , or a single bond; R 2 is selected from: R, OH, OR, CO 2 H, CO 2 R, COH, COR, SO 2 R, CN; R 6 , R 7 and R 9 are independently selected from H, R, OH, OR, halo, amino, NHR, nitro, Me 3 Sn; and R 8 is selected from H, R, OH, OR, halo, amino, NHR, nitro, Me 3 Sn, where R is as defined above, or the compound is a dimer with each monomer being the same or different and being of formula Ia or Ib, where the R 8 groups of the monomers form together a bridge having the formula —X—R′—X— linking the monomers, where R′ is an alkylene chain containing from 3 to 12 carbon atoms, which chain may be interrupted by one or more hetero-atoms and/or aromatic rings and may contain one or more carbon-carbon double or triple bonds, and each X is independently selected from O, S, or N; except that in a compound of formula Ia when A is a single bond, then R 2 is not CH═CH(CONH 2 ) or CH═CH(CONMe 2 ). Other related compounds are also disclosed.

  Ia和Ib的化合物的公式： 其中： A为CH 2 ，或者是一个单键； R 2 从以下选取：R、OH、OR、CO 2 H、CO 2 R、COH、COR、SO 2 R、CN； R 6 、R 7 和R 9 独立地从H、R、OH、OR、卤素、氨基、NHR、硝基、Me 3 Sn中选取； 而R 8 从H、R、OH、OR、卤素、氨基、NHR、硝基、Me 3 Sn中选取，其中R如上所定义，或者该化合物是一个二聚体，每个单体相同或不同，且具有Ia或Ib的式，其中单体的R 8 基共同形成具有式—X—R′—X—的桥，连接单体，其中R′是含有3至12个碳原子的烷基链，该链可以被一个或多个杂原子和/或芳香环打断，并且可以含有一个或多个碳-碳双键或三键，每个X独立地从O、S或N中选取； 除了在Ia的化合物中，当A是一个单键时，那么R 2 不是CH═CH(CONH 2 )或CH═CH(CONMe 2 )。还披露了其他相关化合物。
• [EN] NOVEL ANTI-INFECTIVE AND ANTI-INFLAMMATORY COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS ANTI-INFECTIEUX ET ANTI-INFLAMMATOIRES
  申请人：SYNOVO GMBH

  公开号：WO2018161039A1

  公开（公告）日：2018-09-07

  Lysosomally accumulated substances that release a nitroxy group, or a short chain fatty acid or a product of anaerobic metabolism or a thiol or a sulfide often from an ester or similar labile linkage have anti-inflammatory, anti-cancer and anti-bacterial activity. They are useful in treating infectious, inflammatory and malignant disease.

  溶酶体积累的物质能够释放出一氧化氮基团，或者短链脂肪酸，或者厌氧代谢产物，或者巯基，或者硫化物，通常来自酯类或者类似的易断裂的连接键，它们具有抗炎、抗癌和抗细菌的活性。它们在治疗感染性疾病、炎症性疾病和恶性肿瘤疾病中是有用的。
• [EN] ANTI-INFECTIVE AND ANTI-VIRAL COMPOUNDS AND COMPOSITIONS<br/>[FR] COMPOSÉS ANTI-INFECTIEUX ET ANTIVIRAUX, ET COMPOSITIONS
  申请人：BURNET MICHAEL W

  公开号：WO2021195126A1

  公开（公告）日：2021-09-30

  Lysosomally accumulated substances that release a nitroxy group, or a short chain fatty acid or a product of anaerobic metabolism or a thiol or a sulfide often from an ester or similar labile linkage have anti-inflammatory, anti-cancer and anti-bacterial activity. They are useful in treating infectious, inflammatory and malignant disease and are immune stimulatory, promote zinc uptake, disable endosomal reactions and synergise anti-viral action of protease inhibitors. The compounds are useful for the treatment of bacterial, viral and mixed pneumonias.

  溶酶体积累的物质，能释放硝基氧基团、短链脂肪酸、厌氧代谢产物、硫醇或硫化物，常来自酯或类似不稳定键合，具有抗炎、抗癌和抗菌活性。它们在治疗感染性、炎症性和恶性疾病方面有用，能刺激免疫、促进锌吸收、抑制内体反应并增强蛋白酶抑制剂的抗病毒作用。这些化合物可用于治疗细菌性、病毒性和混合性肺炎。